



## REVIEW ARTICLE

# Usefulness of short tests in dementia screening<sup>☆</sup>

A. Villarejo<sup>\*</sup>, V. Puertas-Martín

Servicio de Neurología, Hospital Universitario Doce de Octubre, Madrid, Spain

Received 10 May 2010; accepted 1 December 2010

### KEYWORDS

Dementia;  
Screening;  
Diagnostic tests;  
Cognitive  
impairment;  
Functional scales

### PALABRAS CLAVE

Demencia;  
Cribado;  
Test diagnósticos;  
Deterioro cognitivo;  
Escala funcionales

### Abstract

**Introduction:** As life expectancy increases, and the prevalence of cognitive impairment and dementia continues to grow, the number of patients with cognitive complaints seen in Primary Care or specialized out-patient clinics has increased in the last few years. The assessment of these patients requires time and a step-by-step organization to optimize medical resources.

**Development:** This review presents the most important dementia screening tools with Spanish validation. We focus on those that are brief (less than 10 min) and easy to use in Primary Care settings. Two groups of tests can be distinguished: brief cognitive tests and functional activities scales. The first can be considered as a part of the mental status examination, and the second as an organized history taking. Informant questionnaires and the possibility of self-administered cognitive tests are briefly reviewed.

**Conclusion:** There are no ideal screening tests. The election of the most appropriate will depend on the physician's time and knowledge of each test. It is advisable to be familiar with a reduced number of tests, and be aware of their strengths and limitations. Finally, we suggest personal recommendations for the most useful tests in each clinical setting.

© 2010 Sociedad Española de Neurología. Published by Elsevier España, S.L. All rights reserved.

## Utilidad de los test breves en el cribado de demencia

### Resumen

**Introducción:** Con el envejecimiento de la población y el consiguiente aumento de la prevalencia de deterioro cognitivo y demencia, el número de pacientes que se presentan con quejas cognitivas en las consultas de atención primaria y especializada se ha disparado en los últimos años. Su evaluación requiere tiempo y una organización asistencial escalonada para optimizar recursos.

**Desarrollo:** En la presente revisión se presentan los principales test de cribado de demencia que han sido estudiados y validados en nuestro medio, destacando aquellos más breves (tiempo de administración menor de 10 minutos) y adecuados para atención primaria. Se pueden dividir en dos grandes grupos: test cognitivos breves (conceptualmente una parte de la exploración

<sup>☆</sup> Please cite this article as: Villarejo A, Puertas-Martín V. Utilidad de los test breves en el cribado de demencia. Neurología. 2011;26:425–33.

<sup>\*</sup> Corresponding author.

E-mail address: [avgalende@yahoo.es](mailto:avgalende@yahoo.es) (A. Villarejo).

nerológica) y escalas funcionales (una parte de la anamnesis, recogida de forma estructurada). Se revisa también la utilidad de los test del informador y la posibilidad de utilizar test autoadministrados.

**Conclusión:** Puesto que no existe el test ideal, la utilización de un test u otro dependerá de la disponibilidad de tiempo y la experiencia del administrador. Conviene familiarizarse con un número reducido de ellos, y conocer tanto sus ventajas como sus limitaciones. Se proponen unas recomendaciones personales sobre los test más adecuados en cada nivel asistencial.

© 2010 Sociedad Española de Neurología. Publicado por Elsevier España, S.L. Todos los derechos reservados.

## Introduction

Population ageing has brought with it an increase in the prevalence of dementia. It is estimated that close to 24 million people around the world suffer some form of dementia and its prevalence will double every 20 years.<sup>1</sup> Early detection and diagnosis have become an important public health problem that has yet to be resolved as various international studies have shown.<sup>2,3</sup> These studies reflect a mean delay of between 8 and 32 months between the onset of symptoms and diagnosis, as well as significant dissatisfaction of caregivers with the ability of Primary Care physicians to diagnose the condition in its initial stages. The benefits of an early diagnosis include doing away with uncertainty, confirming suspicions, enhancing the understanding of the problem, promoting strategies for coping with the disease, facilitating personal planning, having access to treatment, and providing access to social support measures.<sup>4</sup> To date, not a single country has proposed systematic detection in the population of patients with dementia in Primary Care, perhaps due to the limited efficacy of the treatments available, in spite of the fact that it is well known that the percentage of undiagnosed cases is extremely high.<sup>5</sup> In general, "case finding" is recommended<sup>6</sup>; this consists of active screening carried out by the Primary Care physician when facing the detection of a risk factor for the disease. In the case of dementia, these risk factors would be complaints of memory loss, cognitive impairment, or functional decline.

The diagnosis of dementia is clinical, with a limited role so far for biomarkers, and requires a considerable amount of time to collect the information needed for patient anamnesis and examination. Moreover, in most cases, the onset of dementia is gradual and may be difficult to distinguish from ailments such as normal ageing, depression, or pre-existing low intelligence. This time demand placed on doctors collides with the reality of almost all Primary Care clinics and with many neurology outpatient clinics. The mean time per consultation in Primary Care in Europe is 10.7 min,<sup>7</sup> and in Spain it is approximately 5 min, with frequent requests that it be extended to at least 10 min.<sup>8</sup>

The need to elaborate simple, fast tests enabling physicians to detect those individuals who may suffer from dementia or cases in which the diagnosis is doubtful and who require referral for specialized evaluation in just a few minutes with an objective measure is born out of this lack of physician time. The task of providing a measure of a person's cognitive abilities in just a few minutes is a formidable task, which may explain perhaps why there have been such an enormous number of tests proposed and studied in recent

years. In this review article, which in no way seeks to be systematic, the authors intend to provide general practitioners with a practical view of the short tests and scales for the detection of dementia that are most widely used in our setting.

## What is a short test?

The tests that will be reviewed in this article are designed to detect and screen for dementia, and are not for diagnostic purposes, which will always be clinical. It is wise to avoid phrases such as, "the patient has dementia because he/she scores below the cut-off on the test...". As we have previously commented, the diagnosis of dementia is made on a clinical basis; no test can substitute the clinician when establishing the diagnosis.

The ideal short test should meet the following requirements: (a) it must be quick and easy to administer in order to be accepted by professionals; (b) it must be well tolerated and accepted by patients; (c) it must be easy to score, and (d) it must be independent of language, culture, or level of education. Furthermore, it must meet a series of methodological requirements, for instance: (a) good internal consistency; (b) high inter-rater reliability; (c) have good concurrent validity; (d) it must have good predictive and criterion validity, and (e) it must have comparative norms. The interested reader has outstanding reviews of the methodology of diagnostic tests, both general tests,<sup>9</sup> as well as those specifically for dementia.<sup>10,11</sup> In this regard, so as to avoid the heterogeneity of the methods used in validating diagnostic tests, initiatives recently started up, for example the STARD<sup>12</sup> (*Standards for the Reporting of Diagnostic Accuracy*) are of great importance. They attempt to improve the quality of the articles published, verifying that they satisfy a series of requirements, and have already been adopted by many journals, for example, *Neurology*.

The dementia screening tests can be divided into 4 different kinds: cognitive tests, self-administered tests, informant-rated tests, and functional scales. For the purpose of choosing the most appropriate tests for Primary Care, we will set an arbitrary time criterion for cognitive test of approximately 10 min administration time and we will not describe those that have not been validated in our setting, the characteristics of which can be found in other reviews addressing this issue.<sup>13–15</sup> Because of this time criterion, we will also not review short neuropsychological batteries that examine several cognitive domains and that have demonstrated their usefulness for the screening

**Table 1** Screening tests for dementia (\*) and/or Alzheimer's disease (†) validated in our setting.

Test	Cut-off	Sensitivity	Specificity	Area under the curve	Influence of cultural level	Administration time	Test–retest	Consistency
MMSE (†) (Blesa, 2001)	24/25	87.3% (83.8–90.9)	89.2% (83.4–95.0)	—	Yes	8–10 min	0.87 0.96 intraclass	94
MIS (*) (Böhm, 2005)	≤ 4	74%	96%	0.94 (0.92–0.97)	Yes	4 min	0.69	0.67
Phototest (*) (Carnero, 2007)	25/26	88% (80–94)	90% (86–93)	0.95 ± 0.01	No	3 min	—	—
Clock Drawing Test (†) (Cacho, 1999)	6	92.8%	93.5%		Yes	2–3 min	—	0.90
Eurotest (*) (Carnero, 2006)	20/21	91% (84–96)	82% (77–85)	0.93 (0.91–0.95)	No	8–9 min		
SPMSQ (*) (Martínez de la Iglesia, 2001)	> 3 mistakes	85.7%	78.9%	0.892	Yes	3 min	0.738 and 0.925	0.82
AMT (*) (Sarasqueta, 2001)	7/8	91.5%	82.4%	0.90	Yes	3–4 min	—	0.92
M@T (Rami, 2007)* (†)	28	92%	98%	0.997	Yes	5 min	—	0.92

AMT, Abbreviated Mental Test; MIS, Memory Impairment Screen; MMSE, Mini-Mental State Examination; M@T, Memory Alteration Test; SPMSQ, Short Portable Mental Status Questionnaire.

of dementia, such as the 7-min test<sup>16</sup> (mean administration time in excess of 10 min), the Leganés cognitive test<sup>17</sup> (more than 10 min), or the ACE-R<sup>18,19</sup> (*Addenbrooke's Cognitive Examination-Revised*, around 20 min). These batteries yield more information than short tests and can aid in the differential diagnosis among the different causes of dementia; hence, they are more suited to specialized care clinics. Because they are not used in screening, the short tests that assess behavioural or psychiatric symptoms, for instance the BEHAVE-AD<sup>20</sup> or the *Neuropsychiatric Inventory* (NPI),<sup>21</sup> which can be very important in the full evaluation of a patient suspected of having dementia. Most of the tests that will be commented on can be found in monographs about the subject.<sup>22–25</sup>

## Cognitive tests

Short cognitive tests seek to establish an objective measure of the subject's performance on a given task of the examination of the patient's mental status. Therefore, while they are being administered, it is worthwhile to consider them

part of a neurological examination as well as to pay attention to subjective aspects that can provide important information about, for example, attention, motivation, the degree of collaboration, the facility to remember instructions, and the time needed to carry it out (more time is almost invariably needed the more severe the cognitive impairment). [Table 1](#) summarizes the main characteristics of these tests.

## Mini-Mental State Examination (MMSE)

Since it was first introduced by Folstein et al.<sup>26</sup> in 1975, the MMSE has been the most widely used cognitive test in the world and this is probably its greatest advantage, since most of the healthcare personnel involved in evaluating individuals with cognitive impairment are familiar with its use. Moreover, this test has been studied in different populations and for different purposes, such as screening for dementia, to determine its severity, change over time, or response to treatment.<sup>27</sup> Another advantage is that it evaluates more cognitive domains than other short tests, specifically, orientation (10 points), registration (3), concentration and

calculation (5), recall (3), language (8), and constructional praxis (1). Nevertheless, its disadvantages are also numerous (for instance, it cannot be administered to illiterate individuals), and the person's level of general education is influential, which makes adjustment necessary<sup>28</sup> and could decrease its validity.<sup>29</sup> It also has the disadvantage of lacking sensitivity to detect initial phases of dementia, since it barely evaluates executive functions, and the measures of visuo-spatial capacity, episodic memory, and semantics are very crude, which takes away from its validity of content. These shortcomings are especially important in subtypes such as fronto-temporal dementia and Lewy body disease. Even in the case of Alzheimer's disease, due to the fact that it contains only 3 items that explore memory, its performance can be poor in the initial stages or in highly educated people. The disturbance alone of these three items has been associated with an increase in the incidence of dementia<sup>30</sup> and mortality.<sup>31</sup>

Administration time, approximately 10 min, is variable, which is an issue when using it for screening purposes in overwhelmed Primary Care clinics. In a survey given to physicians in the United States, 58% felt that it took too long to administer.<sup>32</sup> Adaptations of the original 30-point version of the MMSE,<sup>28,33</sup> as well as versions with slight modifications<sup>34–37</sup> have been well studied in our setting by different groups. The only versions that have been authorized by the copyright holder are the original 30-point versions,<sup>38</sup> the use of which is more advisable as it enables international comparisons to be more readily made.

### Memory Impairment Screen (MIS)

The MIS is a short test that evaluates recall of 4 words, both free recall as well as semantic cued recall, with a non-semantic distracting task interposed between encoding and recall. Scoring is calculated with a simple arithmetic operation that gives greater weight to free recall ( $2 \times [\text{free recall}] + [\text{cued recall}]$ ). In its original version in English, validated in a community sample,<sup>39</sup> a cut-off of 4 points had 80% sensitivity to detect dementia and 96% specificity. Sensitivity for the diagnosis of Alzheimer's disease was greater (87%), as is logical in a test that only assesses memory. It has been validated in Spain at three units specializing in cognitive impairment,<sup>40–42</sup> obtaining results that are similar to those of the original version. Therefore, although it has not been studied in Spain in community or Primary-Care samples, it can *a priori* be used without problems in these populations. In addition to its validity, similar or superior to that of the MMSE, its main advantages lie in that it is both fast and easy, and its leading disadvantages are that it cannot be administered to illiterate individuals and that it only appraises memory.

### Phototest

Phototest is a brief diagnostic tool, consisting of three parts: naming of 6 objects, a simple verbal fluency test (male and female proper nouns), and, finally, recalling the 6 initial

objects, with both free and semantic cued recall. It is undergoing a strict process of validation: the results of phases I<sup>43</sup> and II<sup>44</sup> have been published and indicate that it is of use for both the detection of cognitive impairment as well as dementia, with 88% sensitivity and 90% specificity for a cut-off of 25/26. Its primary advantages are ease of use, brevity (close to 3 min), and that it is not influenced by level of education and it can be administered to illiterate subjects. As in the case of other very short tests, such as the MIS and the verbal fluency test, its use may be appropriate for screening, but it should be complemented with the use of other tests in order to establish a diagnosis of dementia. The sheets and instructions are available in Spanish at the following website: <http://www.fototest.es>.

### Clock Drawing Test

The Clock Drawing Test is an appealing cognitive task that, in a very short time (2–3 min), explores aspects such as attention, remote memory, visuo-spatial ability, visuo-constructional praxis, and executive functions.<sup>45</sup> Its brevity and clinical usefulness have led some authors to propose it as an ideal screening method for dementia.<sup>46</sup> However, the Clock Drawing Test has two disadvantages for this purpose: on the one hand, it does not assess memory, which makes it inappropriate for the detection of Alzheimer's disease, and on the other hand, it has been poorly accepted and has scant validity in illiterate patients, who are unaccustomed to paper and pencil tasks and who do not perform the test properly. Another issue has to do with the variety of scoring methods, with up to 8 different systems which, despite having a high degree of correlation,<sup>47,48</sup> create some confusion among physicians interpreting it. In our setting, the version that is best validated<sup>49</sup> has a 92.8% sensitivity rate and a specificity rate of 93.5% for the diagnosis of dementia, with a cut-off of 6 out of 10 in drawing to order. Despite its limitations as a screening test, its qualitative scoring is clinically highly practical in the differential diagnosis of dementia and allows the patient's evolution to be observed.

### Eurotest

The Eurotest, an update of the coins test,<sup>50</sup> is based on the subject's knowledge about legally valid coins and notes. It includes language, memory, calculation, capacity of abstraction and executive function tasks. It was designed with the intention of overcoming linguistic, socio-demographic, or cultural influences, and is appropriate for use with illiterate individuals. It has undergone a strict process of validation with preliminary phases,<sup>51</sup> a multicentre, phase-II study,<sup>52</sup> and reliability study,<sup>53</sup> which have yielded satisfactory results: 91% sensitivity and 82% specificity for a cut-off of 20/21, with a high degree of inter- and intra-rater reliability. Perhaps its greatest limitation is that of the time needed to administer it, approximately 8 min, hardly fitting for screening in Primary Care.

## Short Portable Mental Status Questionnaire (SPMSQ)

Also known as Pfeiffer's test,<sup>54</sup> it consists of 10 items that appraise orientation, information, memory, and simple calculation. It is a fast, simple test that can be administered to illiterate patients, although the results are influenced by the person's level of culture; the Spanish version<sup>55</sup> is of limited use with a sensitivity rate of 85.9% and specificity of 78.9% for a cut-off of 3 or more mistakes. It is widely used in Primary Care.

## Hodkinson's Abbreviated Mental Test (AMT)

Hodkinson's test, with its short, 10-point version widely used in the United Kingdom,<sup>56</sup> briefly probes orientation, long term memory, and, to a lesser extent, calculation and facial recognition. It is fast and easy to do, but is influenced by the person's level of culture. In our setting, it has been validated by two groups,<sup>57,58</sup> with adequate performance in community samples, albeit with a degree of methodological limitation.

## Memory Alteration Test (M@T)

The Memory Alteration Test is an innovative test that has been designed and validated for the detection of mild, amnesic, cognitive impairment and Alzheimer's disease in the initial phases.<sup>59,60</sup> It assesses episodic and semantic verbal memory, whose separate analysis provides additional information, given that altered episodic memory aids in distinguishing subjects with mild amnesic cognitive impairment from controls, whereas semantic memory alterations distinguish mild cognitive impairment from Alzheimer's disease. Among its advantages are the brevity and simplicity of administration, as well as good validity for distinguishing both mild amnesic cognitive impairment as well as Alzheimer's disease. Its usefulness as a screening tool for dementia in general has not been appraised, although it is assumed that it will not be as good, as occurs with other tests that only evaluate memory. Its main contribution is probably the early detection of the mild amnesic cognitive impairment in Primary Care.

## Other screening tests

Very short tests used in other countries, but those have not been validated in our setting such as the Mini-Cog<sup>61</sup> (that examines the recall of three words and drawing a clock), and the GPCOG (*General Practitioner Assessment of Cognition*)<sup>62</sup> have not been included in this review. Both are very short and have demonstrated good discriminant validity. Short tests are also beginning to be designed for the early detection of dementia in special situations, such as in Parkinson's disease.<sup>63</sup>

## Self-reported tests

Early results from the validation of a new test, the TYM (*Test Your Memory*) have recently been reported.<sup>64</sup> The authors administered this test in the waiting rooms at a Memory Unit Clinic in the United Kingdom, without the participation of a healthcare professional. The physician's role was limited to interpreting the results handed in by the subjects. The TYM is a short test (approximately 5 min) that examines several cognitive areas and showed better statistical parameters in this study than the MMSE. Undoubtedly, the main advantage of the test is that it does not take any time, although it is not without its disadvantages, such as the influence of the person's level of culture; it cannot be taken by illiterate people; it has a high number of false positive, and it is impossible to determine how much help the patient has received in taking it. Finally, the test is expected to be taken immediately prior to a medical consultation, but the term "self-reported" can lead to confusion and to an indiscriminate use via Internet, where sites are already beginning to appear that offer "the possibility of finding out if you have Alzheimer's", by means of instruments without any kind of scientific validation.<sup>65</sup> A positive result on this type of test can lead to much anguish and give rise to unnecessary consultations. Nonetheless, we are probably facing the first of a series of self-reported cognitive tests. By way of example, an electronic version of the MIS has already been suggested.<sup>66</sup>

## Informant targeted questionnaires

In diagnosing dementia, it is essential to have information provided by a person close to the patient who can describe or confirm the most important clinical traits. Patients are often unaware of their symptoms or minimize them, and it is the relative who can inform as to the true relevance of the problem. For this reason, tests targeting informants yield very useful, complementary information; some of them have even been validated as tools for the screening of dementia, without the use of cognitive tests. In our setting, the one most widely used is the "Test del Informador" (TIN, "Informants' Test" in Spanish; from the original IQCODE [Informant Questionnaire on Cognitive Decline in the Elderly] in English).<sup>67</sup> It comprises a series of questions that are rated from 1 to 5, depending on the current situation versus that of 5 or 10 years earlier. There is a long, 26-question version, as well as a short 17-question versions with greater discriminant power, which is the one that has been validated in the Spanish population.<sup>68,69</sup> It has achieved superior diagnostic performance than the MMSE, without being influenced by age, pre-morbid intelligence, or level of culture. Its disadvantage, as with all questionnaires that target people close to the subject, is related to how reliable the informant actually is. Furthermore, the questions and scoring of the answers have a slight difficulty; which means that it should be administered by a professional, with the consequent time involved (approximately 10–15 min).



**Table 2** Characteristics of the main scales measuring activities of daily living and their performance in the diagnosis of dementia or Alzheimer's disease.

Scale	Administration time	Cut-off	Maximum minimum	Cronbach's $\alpha$	Test—retest	Specificity*	Sensitivity*	Area under the curve
EAIVD (Olazarán, 2005)	5 min	4/5	0–8	0.78	0.95	0.77	0.71	—
B-ADL (Erzigkeit, 2001)	10 min	3.3	1–10	0.98	—	0.72	0.81	0.94 (0.923–0.958)
FAQ (Olazarán, 2005)	8–10 min	5–6	0–33	0.95	0.98	0.88	0.95	0.97 (0.94–0.99)
Blessed (Peña-Casanova, 2005)	10 min	3.5	0–28	0.92	0.98	0.90	0.87	0.96
IDDD (Böhm, 1998)	12–15 min	36	33–99	0.98	0.94	—	—	—

B-ADL, Bayer Activities of Daily Living Scale; Blessed, Blessed Dementia Scale; EAIVD, Lawton and Brody IADL Scale; FAQ, Pfeffer Functional Activity Questionnaire; IDDD, Interview for Deterioration in Daily Living Activities in Dementia; RDRS-2, Rapid Disability Rating Scale.

## Functional scales

One of the DSM-IV diagnostic criteria for dementia is that the alteration of cognitive functions must show significant impairment of the individual's social or occupational activity.<sup>70</sup> The evaluation of the activities of daily living is a core issue in caring for patients with dementia, both for its diagnosis, as well as in charting its evolution. In this regard, as with the short tests, functional scales can be considered a component of the neurological examinations and represent a structured way to record part of the patient's history. Depending on the type of activities being assessed, functional scales can be divided into basic, instrumental, or advanced. The most useful ones for the early detection of dementia are the Instrumental Activities of Daily Living (IADL), i.e. those activities necessary for the individual to be able to interact in their immediate living arrangement and in their community. They depend on the person's physical ability and, to a large extent, their affective, cognitive, and even social setting.<sup>71</sup> They change based on different cultures, communities, and the roles individuals have in their community and are influenced by the subject's gender and age. The most important ones in our setting are: doing housework, cooking meals, using the telephone, using public transportation, managing their own medication, doing laundry or doing the shopping; these IADL are similar across other European countries.<sup>72</sup> The most important instrumental scales that have been validated in Spanish are given in Table 2.

### Lawton and Brody IADL Scale

The Lawton and Brody IADL Scale was created at the Philadelphia Geriatric Center and appraises 8 areas: ability to use the telephone, shopping, food preparation, house-keeping, laundry, mode of transportation, responsibility for

own medication, and ability to handle finances.<sup>73</sup> Each item is rated from 0 to 1, with a minimum score of 0 and a maximum score of 8 (5 in the case of males), depending on the subject's ability. It has good concurrent validity with other scales and with the MMSE. The administration time is short, some 5 min. It is administered by professionals, with good reliability and validity for the diagnosis of Alzheimer's disease, especially if an ordinal scoring system is used instead of the dichotic system currently in use.<sup>74</sup>

### Bayer Activities of Daily Living (B-ADL)

The B-ADL can be used for the early detection of dementia and consists of 25 questions, five of which measure basic activities, 16 rate instrumental activities, and 4 cognitive function.<sup>75</sup> It has been validated by Erzigkeit et al. in Spain and other European countries<sup>76</sup> and it takes 10 min to administer. In the Spanish study, it showed greater discrimination than the MMSE for the diagnosis of dementias in individuals with a low level of culture and is not influenced by age, education, gender, or country of origin.

### Functional Activities Questionnaire

The Functional Activities Questionnaire examines 11 functional activities (managing money, shopping, preparing beverages and food, information about the neighbourhood, understanding of the means of communication, remembering holidays and birthdays, medication, travelling alone, greeting friends, going out alone) and is scored from 0 (totally able) to 3 (totally unable).<sup>77</sup> It takes some 10 min to administer. In adapting it to Spanish, a slight modification from the original was introduced.<sup>74,78</sup> It is sensitive to changes in mild dementia and shows good sensitivity and specificity.<sup>79</sup>

## Blessed Dementia Scale

This scale is specific for dementia.<sup>80</sup> It covers three areas: changes in the activities of daily living (daily chores, money, remembering lists, finding one's way around at home, outside, in familiar environments, ability to grasp situations, remembering recent events, tendency to dwell in the past), changes in habits (in eating, getting dressed, and control of sphincters), and changes in personality, interests and impulses (growing withdrawal, increased self-centredness, loss of interest in feelings, flat affect, loss of emotional control, inappropriate hilarity, diminished emotional response, sexual indiscretions, lack of interest in hobbies, progressive apathy, unjustified hyperactivity). In general terms, it is easy to administer as it is a semi-structured scale, with an approximate duration of 10 min. It has a maximum score of 28 (dependent) and a minimum score 0 (not dependent). It has been validated in Spanish in patients with Alzheimer's disease<sup>81</sup>; it shows good performance and is not influenced by the patient's level of culture or age.

## Interview for Deterioration in Daily Living Activities in Dementia (IDDD)

This dementia-specific scale evaluates both instrumental activities, as well as basic activities, and consists of 33 items, 16 of which explore basic activities.<sup>82</sup> Its scoring ranges from 33 (no functional deterioration) to 99 (dependent). In Spanish, it has been validated within the NORMACODEM Project,<sup>83</sup> as was the previous scale. It has good internal consistency and test–retest reliability and is practical because it evaluates all kinds of ADL, making it a good instrument for the early detection of dementia.

## Final conclusions and recommendations

The short dementia screening tests originate from a very human limitation: lack of time. In a social and health-care environment subjected to growing demands and limited resources, efficiency in the use of physicians' time has become a necessity. There are numerous tests that have proven to be efficacious in the early detection of dementia and the choice of one over another may be influenced by the work setting and the expertise of each professional. It is advisable that professionals be familiar with a small number of tests so as to become more skilful in their use and to be aware of the advantages and limitations of each one. Based on consultation time and level of care, we put forward the following recommendations:

1. Primary Care Clinics (mean time 5–10 min). Two very short tests, the MIS and Phototest, have demonstrated outstanding performance with an administration time of less than 5 min, which makes them the most appropriate in our opinion. In an ideal situation, for instance, if support healthcare personnel are available, it would be of great use to associate an informant questionnaire or a functional scale, which would provide complementary information in Primary Care as it would be capable of

detecting limitations related to other diseases that the patient suffers. With this evaluation, negative cases can be distinguished from positive or doubtful ones, which would require referral to Specialized Care.

2. Specialized Care Clinics (mean time 10–25 min). In this context, short neuropsychological batteries that explore several cognitive areas are more advisable, such as the 7-min test, the ACE-R, or complement the MMSE with tasks that evaluate executive functions, for instance the Clock Drawing Test or phonetic verbal fluency. The recommendation that a functional scale be used is maintained.
3. Specialized Cognitive Impairment Clinics. For typical cases, an evaluation similar to that of Specialized Care may suffice. Doubtful and atypical cases, or those suspected of focal involvement will benefit from a formal neuropsychological examination.

The desired possibility of new treatments appearing in the coming years capable of modifying the course of degenerative disease associated with dementia will make it all the more important for good screening tools to be available.

## Conflict of interests

Alberto Villarejo has received fees for academic and consulting activities from Pfizer, Eisai, Novartis, Grunenthal, and Janssen Cilag. Veronica Puertas-Martín has received research aid from Novartis and Lundbeck, Esteve.

## References

1. Ferri C, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. *Lancet*. 2006;366:2112–7.
2. Bond J, Stave C, Sganga A, et al. Inequalities in dementia care across Europe: key findings of the Facing Dementia Survey. *Int J Clin Pract*. 2005;59 Suppl:8–14.
3. Wilkinson D, Stave C, Keohane D, Vincenzino O. The role of general practitioners in the diagnosis and treatment of Alzheimer's disease: a multinational survey. *J Int Med Res*. 2004;32:149–59.
4. Iliffe S, Robinson L, Brayne C, Goodman C, Rait G, Manthorpe J, et al. Primary care and dementia: 1. Diagnosis, screening and disclosure. *Int J Geriatr Psychiatry*. 2009;24:895–901.
5. Bermejo Pareja F. Reflexiones sobre el cribado (*screening*) de enfermedades neurológicas. *Neurología*. 2003;18 Suppl. 2:29–38.
6. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2001;56:1133–42.
7. Deveugele M, Derese A, van den Brink-Muinene A, Bensing J, De Maeseneer J. Consultation length in general practice: cross sectional study in six European countries. *BMJ*. 2002;325:472.
8. de Pablo González R. Por la calidad y dignidad en la Atención Primaria. Dando sentido a nuestro esfuerzo. *Revista Valenciana de Medicina de Familia*, n° 11 [quoted 1-2011]. Available from: <http://www.svmfyc.org/Revista/11/Pag6.pdf>
9. Gómez de la Cámara A. Caracterización de pruebas diagnósticas. *Neurología*. 2004;19 Suppl. 1:31–8.
10. Carnero-Pardo C. Evaluación de las pruebas diagnósticas. *Rev Neurol*. 2005;40:641–3.

11. Peña-Casanova J, Monllau A, Gramunt-Fombuena N. La psicometría de las demencias a debate. *Neurología*. 2007;22:301–11.
12. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. *BMJ*. 2003;326:41–4.
13. Lorentz WJ, Scanlan JM, Borson S. Brief screening test for dementia. *Can J Psychiatry*. 2002;47:723–33.
14. Brodaty H, Low LF, Gibson L, Burns K. What is the best dementia screening instrument for general practitioners to use? *Am J Geriatr Psychiatry*. 2006;14:391–400.
15. Ismail Z, Rajji TK, Shulman KI. Brief cognitive instruments: an update. *Int J Geriatr Psychiatry*. 2010;25:111–20.
16. Del Ser T, Sánchez-Sánchez F, García de Yébenes MJ, Otero A, Muñoz DG. Validation of the seven-minute screen neurocognitive battery for the diagnosis of dementia in a Spanish population-based sample. *Dement Geriatr Cogn Disord*. 2006;22:454–64.
17. De Yébenes MJ, Otero A, Zonzunegui MV, Rodríguez-Laso A, Sánchez-Sánchez F, Del Ser T. Validation of a short cognitive tool for the screening of dementia in elderly people with low educational level. *Int J Geriatr Psychiatry*. 2003;18:925–36.
18. Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR. The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. *Int J Geriatr Psychiatry*. 2006;21:1078–85.
19. García-Caballero A, García-Lado I, González-Hermida J, Recimil M, Area R, Manes F, et al. Validation of the Spanish version of the Addenbrooke's Cognitive Examination in a rural community in Spain. *Int J Geriatr Psychiatry*. 2006;21:239–45.
20. Sclan S, Saillon A, Franssen E, Hugonot-Diener L, Saillon A, Reisberg B. The behavior pathology in Alzheimer's disease rating scale (BEHAVE-AD): reliability and analysis of symptom category scores. *Int J Geriatr Psychiatry*. 1996;11:819–30.
21. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. *Neurology*. 1994;44:2308–14.
22. Peña-Casanova J, Gramunt N, Gich J. Test neuropsicológicos: Fundamentos para una neuropsicología basada en evidencias. Barcelona: Masson; 2004.
23. Bermejo Pareja F, Villanueva Iza C, Rodríguez C, Villarejo A. Escalas de utilidad en la evaluación de la alteración cognitiva y demencia. In: Bermejo Pareja F, Porta-Etessam J, Díaz-Guzmán J, Martínez-Martín P, editors. Más de cien escalas en Neurología. Madrid: Aula Médica; 2008.
24. Bermejo Pareja F, Castilla Rilo J. Escalas funcionales. In: Bermejo Pareja F, Porta-Etessam J, Díaz-Guzmán J, Martínez-Martín P, editors. Más de cien escalas en Neurología. Madrid: Aula Médica; 2008. p. 87–108.
25. Burns A, Lawlor B, Craig S. Assessment scales in old age psychiatry. Andover: Thomson Publishing Services; 2004.
26. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975;12:189–98.
27. Tombaugh TN, McIntyre NJ. The Mini-Mental State Examination: a comprehensive review. *J Am Geriatr Soc*. 1992;40:922–35.
28. Blesa R, Pujol M, Aguilar M, Santacruz P, Bertran-Serra I, Hernández G, et al. Clinical validity of the 'mini-mental state' for Spanish speaking communities. *Neuropsychologia*. 2001;39:1150–7.
29. Kraemer HC, Moritz DJ, Yesavage J. Adjusting Mini-Mental State Examination scores for age and educational level to screen for dementia: correcting bias or reducing validity? *Int Psychogeriatr*. 1998;10:43–51.
30. Olazarán J, Trincado R, Bermejo F, Benito-León J, Díaz J, Vega S. Selective memory impairment on an adapted Mini-Mental State Examination increases risk of future dementia. *Int J Geriatr Psychiatry*. 2004;19:1173–80.
31. Villarejo A, Bermejo-Pareja F, Trincado R, Olazarán J, Benito-León J, Rodríguez C, et al. Memory impairment in a simple recall task increases mortality at 10 years in non-demented elderly. *Int J Geriatr Psychiatry*. 2010. In press.
32. Tangalos E, Smith G, Ivnik R, Petersen R, Kokmen E, Kurland L, et al. The mini-mental state examination in general medical practice: clinical utility and acceptance. *Mayo Clin Proc*. 1996;71:829–37.
33. Manubens JM, Martínez-Lage P, Martínez-Lage JM, Larumbe R, Muruzábal J, Martínez-González MA, et al. Variación de las puntuaciones en el Mini-Mental-State con la edad y el nivel educativo. Datos normalizados en la población mayor de 70 años de Pamplona. *Neurología*. 1998;13:111–9.
34. Bermejo F, Morales JM, Valerga C, Del Ser T, Artolazabal J, Gabriel R. Comparación entre dos versiones españolas abreviadas de evaluación del estado mental en el diagnóstico de demencia. Datos de un estudio en ancianos residentes en la comunidad. *Med Clin*. 1999;112:330.
35. Bermejo F, Gómez-Isla T, Morales JM. El Mini-Mental State Examination en la evaluación del deterioro cognitivo y la demencia. In: Del Ser T, Peña J, editors. Evaluación neuropsicológica y funcional de la demencia. Barcelona: JR Prous Editores; 1994. p. 93–107.
36. Lobo A, Ezquerro J, Gómez F, Sala J, Seva A. El Mini-Examen Cognoscitivo: un test sencillo, práctico, para detectar alteraciones intelectivas en pacientes médicos. *Actas Luso-Esp Neurol Psiquiatr*. 1979;3:189–92.
37. Lobo A, Saz P, Marcos G, Día JL, de la Cámara C, Ventura T, et al. Revalidación y normalización del Mini-Examen Cognoscitivo (primera versión en castellano del Mini-Mental Status Examination) en la población general geriátrica. *Med Clin*. 1999;112:767–74.
38. Página web de Psychological Assessment Resources, Inc. Available from: <http://www4.parinc.com/http://www4.parinc.com/Products/Product.aspx?ProductID=MMSE-2>.
39. Buschke H, Kuslansky G, Katz M, Stewart WF, Sliwinski MJ, Eckholdt HM, et al. Screening for dementia with the memory impairment screen. *Neurology*. 1999;52:231–8.
40. Pérez-Martínez DA, Baztán JJ, González-Becerra M, Socorro A. Evaluación de la utilidad diagnóstica de una adaptación española del *Memory Impairment Screen* de Buschke para detectar demencia y deterioro cognitivo. *Rev Neurol*. 2005;40:644–8.
41. Böhm P, Peña-Casanova J, Gramunt N, Manero RM, Terrón C, Quiñones-Ubeda S. Versión española del *Memory Impairment Screen* (MIS): datos normativos y validez discriminativa. *Neurología*. 2005;20:402–11.
42. Barrero-Fernández FJ, Vives-Montero F, Morales-Gordo B. Evaluación de la versión española del *Memory Impairment Screen*. *Rev Neurol*. 2006;43:15–9.
43. Carnero Pardo C, Montoro Ríos M. El Test de las Fotos. *Rev Neurol*. 2004;39:801–6.
44. Carnero Pardo C, Montoro Ríos M. Utilidad diagnóstica del Test de las Fotos (Fototest) en deterioro cognitivo y demencia. *Neurología*. 2007;22:860–9.
45. Googlass H, Kaplan E. Supplementary language test. In: The assessment of aphasia and related disorders. Philadelphia: Lea and Febiger; 1972.
46. Shulman KI. Clock drawing: is it the ideal cognitive screening test? *Int J Geriatr Psychiatry*. 2000;15:548–61.
47. Brodaty H, Moore CM. The clock drawing test for dementia of the Alzheimer's type: a comparison of three scoring methods in a memory disorders clinic. *Int J Geriatr Psychiatry*. 1997;12:619–27.
48. García-Caballero A, Recimil MJ, García-Lado I, Gayoso P, Cadarso-Suárez C, González-Hermida J, et al. ACE clock scoring:



- a comparison with eight standard correction methods in a population of low educational level. *J Geriatr Psychiatry Neurol.* 2006;19:216–9.
49. Cacho J, García-García R, Arcaya J, Vicente JL, Lantada N. Una propuesta de aplicación y puntuación del Test del Reloj en la enfermedad de Alzheimer. *Rev Neurol.* 1999;28:648–55.
  50. Carnero C, Lendínez E, Navarro E. El test de las monedas. *Rev Neurol.* 1999;29:801–4.
  51. Carnero-Pardo C, Montoro-Ríos M. Evaluación preliminar de un nuevo test de cribado de demencia (EUROTEST). *Rev Neurol.* 2004;38:201–9.
  52. Carnero-Pardo C, Gurpegui M, Sánchez-Cantalejo E, Frank A, Mola S, Barquero MS, et al. Diagnostic accuracy of the Eurotest for dementia: a naturalistic, multicenter phase II study. *BMC Neurol.* 2006;6:15.
  53. Carnero-Pardo C, Gurpegui M, Sánchez-Cantalejo E, Gómez-Camello A, Guardado-Santervás P, Montoro-Ríos M. Evaluación de la fiabilidad del EUROTEST. *Neurología.* 2007;22:153–8.
  54. Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. *J Am Geriatr Soc.* 1975;23:433–41.
  55. Martínez de la Iglesia J, Dueñas Herrero R, Onís Vilches M, Aguado Taberné C, Albert Colomer C, Luque Luque R. Adaptación y validación al castellano del cuestionario de Pfeiffer (SPMSQ) para detectar la existencia de deterioro cognitivo en personas mayores de 65 años. *Med Clin.* 2001;117:129–34.
  56. Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. *Age Ageing.* 1972;1:233–8.
  57. Gómez de Caso JA, Rodríguez-Artalejo F, Clavería LE, Coria F. Value of Hodkinson's test for detecting dementia and mild cognitive impairment in epidemiological surveys. *Neuroepidemiology.* 1994;13:64–8.
  58. Sarasqueta C, Bergareche A, Arce A, López de Munain A, Poza JJ, De La Puente E, et al. The validity of Hodkinson's Abbreviated Mental Test for dementia screening in Guipuzcoa. Spain *Eur J Neurol.* 2001;8:435–40.
  59. Rami L, Molinuevo JL, Sánchez-Valle R, Bosch B, Villar A. Screening for amnesic mild cognitive impairment and early Alzheimer's disease with M@T (Memory Alteration Test) in the primary care population. *Int J Geriatr Psychiatry.* 2007;22:294–304.
  60. Rami L, Bosch B, Sánchez-Valle R, Molinuevo JL. The memory alteration test (M@T) discriminates between subjective memory complaints, mild cognitive impairment and Alzheimer's disease. *Arch Gerontol Geriatr.* 2010;50:171–4.
  61. Borson S, Scanlan J, Brush M, Vitaliano P, Dokmak A. The Mini-Cog: a cognitive 'vital signs' measure for dementia screening in multilingual elderly. *Int J Geriatr Psychiatry.* 2000;15:1021–7.
  62. Brodaty H, Pond D, Kemp NM, Luscombe G, Harding L, Berman K, et al. The GPCOG: a new screening test for dementia designed for general practice. *J Am Geriatr Soc.* 2002;50:530–4.
  63. Pagonabarraga J, Kulisevsky J, Llebaria G, García-Sánchez C, Pascual-Sedano B, Martínez-Corral M, et al. PDD-Short Screen: a brief cognitive test for screening dementia in Parkinson's disease. *Mov Disord.* 2010;25:440–6.
  64. Brown J, Pengas G, Dawson K, Brown LA, Clatworthy P. Self administered cognitive screening test (TYM) for detection of Alzheimer's disease: cross sectional study. *BMJ.* 2009;338:b2030.
  65. Cherbuin N, Anstey KJ. DIY dementia screening and online assessment tools. *Int Psychogeriatr.* 2008;20:641–2.
  66. Cherbuin N, Anstey KJ, Lipnicki DM. Screening for dementia: a review of self- and informant-assessment instruments. *Int Psychogeriatr.* 2008;20:431–58.
  67. Jorm AF, Korten AE. Assessment of cognitive decline in the elderly by informant interview. *Br J Psychiatry.* 1988;152:209–13.
  68. Morales JM, González-Montalvo JI, Bermejo F, Del Ser T. The screening of mild dementia with a shortened Spanish version of the informant questionnaire on cognitive decline in the elderly. *Alzheimer Dis Assoc Disord.* 1995;9:105–11.
  69. Morales JM, González-Montalvo JI, Bermejo F, Del Ser T. Screening of dementia in community-dwelling elderly through informant report. *Int J Geriatr Psychiatry.* 1997;12:808–16.
  70. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th ed., text revision) DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000.
  71. McDowell I, Newell C. Measuring health. A guide to rating scales and questionnaire. New York: Oxford University Press; 1987.
  72. Nikula S, Jylha M, Bardage C. Are IADLs comparable across countries? Sociodemographic associates of harmonized IADL measures. *Aging Clin Exp Res.* 2003;15:451–9.
  73. Lawton MP, Brody EM. Assessment of other people: self-maintaining and instrumental activities of daily living. *Gerontologist.* 1968;9:179–86.
  74. Olazarán J, Mouronte P, Bermejo F. Validez clínica de dos escalas de actividades instrumentales en la enfermedad de Alzheimer. *Neurología.* 2005;20:395–401.
  75. Hindmarch I, Leffeld H, De Jong P, Erzigkeit H. The Bayer activities of daily living scale (B-ADL). *Dement Geriatr Cogn Disord.* 1998;9:20–6.
  76. Erzigkeit H, Leffeld H, Peña-Casanova J, Bieber F, Yekrang C, Rupp M, et al. The Bayer-Activities of Daily Living Scale (B-ADL): results from a validation study in three European countries. *Dement Geriatr Cogn Disord.* 2001;12:348–58.
  77. Pfeffer RI, Kurosaki TT, Chance JM, Filos S, Bates D. Use of the mental function index in older adults. Reliability, validity, and measurement of change over time. *Am J Epidemiol.* 1984;120:922–35.
  78. Villanueva-Iza C, Bermejo-Pareja F, Berbel-García A, Trincado-Soriano R, Rivera-Navarro J. Validación de un protocolo clínico para la detección de demencia en ámbito poblacional. *Rev Neurol.* 2003;36:1121–6.
  79. Castilla-Rilo J, López-Arrieta J, Bermejo-Pareja F, Ruiz M, Sánchez-Sánchez F, Trincado R. Instrumental activities of daily living in the screening of dementia in population studies: a systematic review and meta-analysis. *Int J Geriatr Psychiatry.* 2007;22:829–36.
  80. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. *Br J Psychiatry.* 1968;114:797–811.
  81. Peña-Casanova J, Monllau A, Böhm P, Aguilar M, Sol JM, Hernández G, et al. Grupo NORMACODEM. Valor diagnóstico de la escala de demencia de Blessed para la enfermedad de Alzheimer: datos del proyecto NORMACODEM. *Neurología.* 2005;20:349–55.
  82. Teunisse S, Derix MM, Crevel H. Assessing the severity of dementia. Patient and caregiver. *Arch Neurol.* 1991;48:274–7.
  83. Böhm P, Peña-Casanova J, Aguilar M, Hernández G, Sol JM, Blesa R. Clinical validity and utility of the interview for deterioration of daily living in dementia for Spanish-speaking communities. *Int Psychogeriatr.* 1998;10:261–70.